GK Q&A, page-43

RBx, following on from your Breakthrough Designation comments, IMO it is possible for Trilexium to receive this for the treatment of DIPG which would shorten the testing requirements. Trilexium, for the treatment of DIPG could then apply for a Rare Pediatric Disease Priority Review Voucher. These vouchers can be used to fast track the application for marketing approval to a period of 6 months, as opposed to 18 months. The voucher is also transferable and can be sold to another company for a considerable amount; Retrophin Agrees to Sell Priority Review Voucher to Sanofi

I would appreciate your opinion on this.